Wedbush Research Analysts Cut Earnings Estimates for CAKE

Wedbush Research Analysts Lower Earnings Estimates For CAKE

1 week from now

Oct 30, 2024  · Wedbush currently has a “Outperform” rating and a $45.00 target price on the stock. The consensus estimate for Cheesecake Factory’s current full-year earnings is $3.21 …

americanbankingnews.com

Q4 EPS Estimates For Cheesecake Factory Reduced By Wedbush

1 week from now

Oct 28, 2024  · The consensus estimate for Cheesecake Factory’s current full-year earnings is $3.21 per share. Wedbush also issued estimates for Cheesecake Factory’s Q4 2025 earnings …

defenseworld.net

Wedbush Decreases Earnings Estimates For Cheesecake Factory

1 week from now

Nov 1, 2024  · Wedbush currently has a “Outperform” rating and a $52.00 target price on the stock. The consensus estimate for Cheesecake Factory’s current full-year earnings is $3.21 …

defenseworld.net

Cheesecake Factory (NASDAQ:CAKE) Earns Outperform Rating …

1 week from now

Nov 8, 2024  · Cheesecake Factory had a net margin of 3.63% and a return on equity of 45.66%. The company's quarterly revenue was up 4.3% on a year-over-year basis. During the same …

marketbeat.com

Wedbush Sticks To Its Buy Rating For Cheesecake Factory (CAKE)

1 week from now

3 days ago  · In a report released today, Nick Setyan from Wedbush maintained a Buy rating on Cheesecake Factory (CAKE – Research Report), with a price target of $59.00.The company’s …

businessinsider.com

The Cheesecake Factory (CAKE) Reports Earnings Tomorrow: What …

1 week from now

Oct 28, 2024  · The Cheesecake Factory met analysts’ revenue expectations last quarter, reporting revenues of $904 million, up 4.4% year on year. It was a strong quarter for the …

wedbush.com

FY2024 EPS Estimates For Fate Therapeutics Cut By Wedbush

1 week from now

13 hours ago  · Wedbush currently has a “Neutral” rating and a $5.00 target price on the stock. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.73) per share. …

etfdailynews.com

Q4 EPS Estimates For Boston Properties Reduced By Wedbush

1 week from now

13 hours ago  · The real estate investment trust reported $0.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.81 by ($1.28). Boston Properties had a return …

defenseworld.net

Research Analysts Offer Predictions For HPP FY2024 Earnings

1 week from now

13 hours ago  · The consensus estimate for Hudson Pacific Properties’ current full-year earnings is $0.54 per share. Wedbush also issued estimates for Hudson Pacific Properties’ Q4 2024 …

etfdailynews.com

Wedbush Lowers Earnings Estimates For ORIC Pharmaceuticals

1 week from now

1 day ago  · Wedbush currently has a “Outperform” rating and a $20.00 target price on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($1.80) per …

defenseworld.net

Equities Analysts Offer Predictions For ANRO FY2024 Earnings

1 week from now

1 day ago  · Wedbush currently has a “Neutral” rating and a $4.00 price objective on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.63) per …

etfdailynews.com

The Case For $4 Trillion - Nasdaq

1 week from now

2 days ago  · Wedbush analyst Dan Ives calculates there are an estimated 300 million active iPhones that are at least four years old. With more breathing room in their budgets, it's …

nasdaq.com

Wedbush Forecasts Higher Earnings For ITeos Therapeutics

1 week from now

13 hours ago  · Wedbush currently has a “Outperform” rating and a $25.00 target price on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.64) per …

americanbankingnews.com